Cystic Fibrosis – Pipeline Assessment and Market Forecasts to 2017

GlobalData’s pharmaceutical and healthcare report, “Cystic Fibrosis - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global cystic fibrosis market. The report identifies the key trends shaping and driving the global cystic fibrosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global cystic fibrosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Companies Mentioned

Cystic Fibrosis Foundation Therapeutics, Inc.
Pharmaxis Ltd
Gilead Sciences, Inc
Vertex Pharmaceuticals, Inc
AstraZeneca
PARI Pharma
[Studien Infos ausblenden]

LIST OF TABLES

1.1 List of Tables
Table 1: Cystic Fibrosis Therapeutics Market, Global, Revenue ($m), 2001–2009 8
Table 2: Cystic Fibrosis Therapeutics Market, Global, Forecast Revenue ($m), 2009–2017 9
Table 3: Major Marketed Products Analysis in Cystic Fibrosis Therapeutics Market, 2010 17
Table 4: Cystic Fibrosis – Most Promising Drugs Under Clinical Development, 2010 20
Table 5: Cystic Fibrosis – Phase III Clinical Pipeline, 2010 25
Table 6: Cystic Fibrosis – Phase II Clinical Pipeline, 2010 26
Table 7: Cystic Fibrosis – Phase I Clinical Pipeline, 2010 28
Table 8: Cystic Fibrosis – Preclinical Pipeline, 2010 29
Table 9: Cystic Fibrosis – Discovery Pipeline, 2010 29
Table 10: Discontinued Drugs for Cystic Fibrosis, 2010 30
Table 11: CFFT – Cystic Fibrosis Marketed Products, 2010 33
Table 12: CFFT – Cystic Fibrosis Pipeline Portfolio, 2010 33
Table 13: Pharmaxis Ltd – Respiratory Marketed Product, 2010 35
Table 14: Pharmaxis Ltd – Respiratory Pipeline Portfolio, 2010 35
Table 15: Gilead Sciences, Inc – Respiratory Pipeline Portfolio, 2010 37
Table 16: Vertex Pharmaceuticals Inc – Respiratory Pipeline Portfolio, 2010 38
Table 17: AstraZeneca – Respiratory Marketed Products, 2010 40
Table 18: AstraZeneca – Respiratory Pipeline Portfolio, 2010 40
Table 19: Pari Pharma – Respiratory Marketed Products, 2010 41
Table 20: Pari Pharma – Respiratory Pipeline Portfolio, 2010 41

LIST OF FIGURES

1.2 List of Figures
Figure 1: Cystic Fibrosis Therapeutics Market, Global, Revenues ($m), 2001–2009 8
Figure 2: Cystic Fibrosis Therapeutics Market, Global, Forecast Revenues ($m), 2009–2017 9
Figure 3: Opportunity and Unmet Need in Cystic Fibrosis Market, 2010 11
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Cystic Fibrosis, 2010 12
Figure 5: Technology Trends Analytic Framework of the Cystic Fibrosis Pipeline, 2010 19
Figure 6: Technology Trends Analytic Framework of the Cystic Fibrosis Pipeline – Description, 2010 20
Figure 7: Cystic Fibrosis – Clinical Pipeline by Mechanism of Action, 2010 24
Figure 8: Cystic Fibrosis – Pipeline by Phase of Clinical Development, 2010 25
Figure 9: Cystic Fibrosis – Implications for the Future Market Competition, 2010 31
Figure 10: Cystic Fibrosis Therapeutics – Clinical Pipeline by Company , 2010 32
Figure 11: GlobalData Methodology 44
Figure 12: GlobalData Market Forecasting Model 47
[Tabellenverzeichnis ausblenden]